Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Ann Surg Oncol. 2018 Oct 11;25(13):4037–4046. doi: 10.1245/s10434-018-6859-x

Figure 4.

Figure 4.

Cumulative incidence rate analysis using the three-miRNA signature score for each metastatic site (bone, n=41; local recurrence, n=15; lung, n=12, other, n=15). (A) Bone met associated significantly with high three-miRNA signature score. (B) Patients that developed recurrent bone metastasis showed higher levels of the three-miRNA signature score compared from matched control patients that did not (control breast cancer group, n=10; bone recurrence group, n=10; p=0.1847). (C) ROC curve using the three-miRNA signature score derived from miRNA-Seq data of the 20 primary tissue samples showed AUC of 0.71; Sensitivity, 0.90; specificity, 0.65; accuracy 0.75.